Different formula of supplement on micronutrient,
Conditions
Interventions
A subject who receive Vitamin C,
Vitamin D3,
Q10 and antioxidant formula of HCK®,A subject who receive the original VTL* supplement of Vitamin C,
Q10 and antioxidant ,A subject who has no supplement received
HCK,VTL,No supplement
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Subjects aged ≥ 18 years who visit Vital-life wellness center for micronutrient level assessment and decide to receive either Vitamin C, Vitamin D3, CO-Q10 and antioxidant formula of HCK® or The original VTL supplement of Vitamin C, Vitamin D3, CO-Q10 and antioxidant or no supplement after discussion for possible treatment options with physician as usual practice 2.Subjects found to have low level of 25-(OH)D3/D2 (having 25-(OH)D3/D2 level 20-29 ng/ml) with the symptoms or feelings of low energy, lack of vitality or tiredness 3.Subjects who have not taken coenzyme Q10, vitamin C, vitamin D3, vitamin E, carotenoids, and flavonoids for at least 3 months and vitamin A for at least 6 months 4.Willing and able to comply with study procedure.
Exclusion criteria
Exclusion criteria: 1. Subjects with poorly controlled underlying diseases such as poor control of Blood Pressure (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg), poor control of blood sugar (HbA1c > 7%). 2. Subjects with eGFR < 30 ml/min/1.73 m2 3. Female subjects who are pregnant or lactating, or plan to have children (a negative serum or urine pregnancy test is required on the screening day for women of child-bearing potential). 4. Subjects with diseases that may interfere with supplement absorption e.g., patients with malabsorption and bowel surgery. 5. Subjects using medication that may interfere with micronutrient levels such as acid suppressants, antacids, antiepileptic drugs (i.e., phenobarbital, valproic acid, carbamazepine, phenytoin), and antipsychotic drugs (i.e., tricyclic antidepressants and haloperidol). However, subjects who stop using these medications for at least 1 month prior to the enrollment can be included into the study. 6. Subjects with vitamin D deficiency or having underlying diseases that require treatment with vitamin D such as osteoporosis and primary hyperparathyroidism 7. Subjects who is currently smoking. 8. Subjects with history of allergy to vitamins and supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Selected micronutrient levels month3 and month 6 STATA | — |
Secondary
| Measure | Time frame |
|---|---|
| QoL month3 and month6 Chi square | — |
Contacts
Public ContactNawin Jittet
Bumrungrad Hospital
Outcome results
None listed